Edition:
India

Zynerba Pharmaceuticals Inc (ZYNE.OQ)

ZYNE.OQ on NASDAQ Stock Exchange Global Market

14.19USD
10:04pm IST
Change (% chg)

$-0.40 (-2.74%)
Prev Close
$14.59
Open
$14.50
Day's High
$14.60
Day's Low
$14.13
Volume
40,655
Avg. Vol
227,942
52-wk High
$25.95
52-wk Low
$5.42

Select another date:

Tue, Nov 14 2017

BRIEF-Zynerba Pharmaceuticals reports Q3 loss per share of $0.63

* Zynerba Pharmaceuticals reports third quarter 2017 financial results and operational highlights

Zynerba's stock on a high as cannabis-based drug succeeds in trial

Zynerba Pharmaceuticals Inc said on Thursday its cannabis-derived gel to treat genetic disorder Fragile X syndrome succeeded in significantly reducing symptoms such as anxiety in a mid-stage study.

BRIEF-Zynerba Pharmaceuticals announces positive top line results in ZYN002 open label Phase 2 FAB-C study

* Zynerba Pharmaceuticals announces positive top line results in ZYN002 open label Phase 2 FAB-C study in children with Fragile X syndrome

Zynerba's cannabis-based gel succeeds in mid-stage study

Sept 28 Zynerba Pharmaceuticals Inc said on Thursday its cannabis-based gel succeeded in a mid-stage study of patients with Fragile X syndrome, a genetic disorder that causes learning disabilities.

BRIEF-Zynerba Pharmaceuticals announces results from phase 2 STOP clinical trial

* Zynerba Pharmaceuticals announces that results from phase 2 stop trial support continued development of ZYN002 in osteoarthritis

Zynerba shares plunge as cannabis-based epilepsy gel fails study

Zynerba Pharmaceuticals Inc's stock lost more than half its value on Monday after the U.S. drug developer said its synthetic cannabis-based gel for epilepsy failed a mid-stage study.

UPDATE 2-Zynerba shares plunge as cannabis-based epilepsy gel fails study

* ZYNE stock sinks about 60 pct, GW shares rise 4 pct (Adds analysts' comments, conf. call details, GW shares; updates ZYNE shares)

Zynerba's cannabis-based gel for epilepsy fails study

Aug 7 Zynerba Pharmaceuticals said on Monday its experimental synthetic cannabis-based gel failed to induce a statistically significant reduction in seizures in a mid-stage study involving epilepsy patients.

BRIEF-Zynerba Pharma announces top-line results from phase 2 star 1 trial of ZYN002

* Zynerba Pharmaceuticals announces top-line results from phase 2 star 1 trial of ZYN002 in adult epilepsy patients with focal seizures

BRIEF-Zynerba Pharmaceuticals reports second quarter 2017 results

* Zynerba Pharmaceuticals reports second quarter 2017 financial results and operational highlights

Select another date: